Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

Rui-Lan Huang; Hui Chen Wang; Hung-Cheng Lai

doi:10.1016/j.bgm.2013.08.022

Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

Rui-Lan Huang, Hui Chen Wang, Hung-Cheng Lai

Research output: Contribution to journal › Article › peer-review

Abstract

The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

Original language	Chinese (Traditional)
Pages (from-to)	125
Number of pages	1
Journal	Biomarkers and Genomic Medicine
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.bgm.2013.08.022
Publication status	Published - Sept 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bgm.2013.08.022

http://www.sciencedirect.com/science/article/pii/S2214024713000919

Cite this

Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine. / Huang, Rui-Lan; Wang, Hui Chen; Lai, Hung-Cheng.
In: Biomarkers and Genomic Medicine, Vol. 5, No. 3, 09.2013, p. 125.

Research output: Contribution to journal › Article › peer-review

@article{757b0993bc7b4f078a7dd03a60de11fb,

title = "Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures: 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine",

abstract = "The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.",

author = "Rui-Lan Huang and Wang, {Hui Chen} and Hung-Cheng Lai",

year = "2013",

month = sep,

doi = "10.1016/j.bgm.2013.08.022",

language = "中文",

volume = "5",

pages = "125",

journal = "Biomarkers and Genomic Medicine",

issn = "2214-0247",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Methylomic deep sequencing of ovarian cancer reveals diagnostic and prognostic signatures

T2 - 2013 Annual Meeting of the Taiwan Genomic Medicine and Biomarker Society Symposium on Clinical Application of Genomic Medicine

AU - Huang, Rui-Lan

AU - Wang, Hui Chen

AU - Lai, Hung-Cheng

PY - 2013/9

Y1 - 2013/9

N2 - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

AB - The heterogeneity of ovarian cancer requires biomarkers for personalized medicine. DNA methylation aberration is a hallmark of cancer. The attempt of using DNA methylation as biomarkers for prognosis prediction is appealing. Methylomic analysis using next generation sequencing technology has never been applied in ovarian cancer research. The present study for the first time is to explore the methylomics of ovarian cancer using this cutting edge technology.

U2 - 10.1016/j.bgm.2013.08.022

DO - 10.1016/j.bgm.2013.08.022

M3 - 文章

SN - 2214-0247

VL - 5

SP - 125

JO - Biomarkers and Genomic Medicine

JF - Biomarkers and Genomic Medicine

IS - 3

ER -